Privacy preference

MEDtalks would like to keep you informed about the content that is most relevant to you. Click here for more information.


EHA 25 European Perspectives Webinar: AML

Published on: 22.06.2020, 30 min.

In this webinar, Prof. Dr. Nigel Russel, MD and Prof. Dr. Gert Ossenkoppele discuss two practice changing studies on AML.

Study 1 summarised by Prof. Dr. Nigel Russell MD

(S144) THE FIRST-IN-CLASS ANTI-CD47 ANTIBODY MAGROLIMAB COMBINED WITH AZACITIDINE IS WELL-TOLERATED AND EFFECTIVE IN AML PATIENTS: PHASE 1B RESULTS

Study 2 summarised by Prof. Dr. Gert Ossenkoppele

(LB2601) A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF VENETOCLAX WITH AZACITIDINE VS AZACITIDINE IN TREATMENT-NAÏVE PATIENTS WITH ACUTE MYELOID LEUKEMIA INELIGIBLE FOR INTENSIVE THERAPY-VIALE-A

 

The webinar was independently produced and paid for by the MEDtalks Group of Companies.

  • Partner


    This program has been produced by our partner: